Summary
The aim of The LiMA Study is to test if lisdexamfetamine is effective in reducing methamphetamine use, cravings and withdrawal symptoms. 180 people with methamphetamine dependence will be recruited to the LiMA Study, which will be conducted in specialist treatment centres in Sydney, Newcastle, Adelaide and Melbourne. Participants will be randomly assigned to receive either a 15-week intervention consisting of induction (1 week of 150mg lisdexamfetamine [LDX] or placebo), maintenance (12 weeks of 250mg LDX or placebo) and reduction (1 week of 150mg LDX or placebo and 1 week of 50mg LDX or placebo). All participants will be given access to 4 sessions of Cognitive Behaviour Therapy (CBT) as treatment-as-usual and receive a 4-week follow up appointment.
The LiMA study is no longer recruiting. This study has been approved by the Human Research Ethics Committee of St. Vincent’s Hospital, Sydney, Australia (HREC/16/SVH/222).
Investigators
Prof Nadine Ezard
SVHS/UNSW/National Centre for Clinical Research on Emerging Drugs
Prof Adrian Dunlop
Hunter New England LHD/Drug and Alcohol Clinical Services
Michelle Hall
Drug and Alcohol Clinical Services, Hunter New England
A/Prof Robert Ali
UNSW / University of Adelaide
Prof Raimondo Bruno
School of Medicine, University of Tasmania
A Prof Rebecca McKetin
Curtin University, Perth, Western Australia / NDARC / UNSW
Dr Nghi Phung
Western Sydney Local Health District, Sydney
Prof Andrew Carr
Alcohol and Drug Service, St Vincents Hospital, Sydney / University of New South Wales
Jason White
University of South Australia
Brendan Clifford
SVHS / Sydney Nursing School, University of Sydney
Dr Xhixin Liu
UNSW
Marian Shanahan
National Drug and Alcohol Research Centre, UNSW Sydney
Prof Kate Dolan
National Drug and Alcohol Research Centre, UNSW
Prof Amanda L. Baker
School of Medicine and Public Health, University of Newcastle
Prof Nicholas Lintzeris
University of Sydney/South East Sydney LHD/Drug and Alcohol Servic